Diffuse large B Cell lymphoma: How can we cure more patients in 2012?

Clinically this chapter will focus on 3 important issues critical in the management of diffuse large B cell lymphoma (DLBCL) in 2012: risk stratification, interim PET-CT scanning and the role of high dose therapy and ASCT in the rituximab era for patients with relapsed and primary refractory disease. (C) 2012 Elsevier Ltd. All rights reserved.